Search results for "dosage"

showing 10 items of 516 documents

Solid and Semisolid Innovative Formulations Containing Miconazole-Loaded Solid Lipid Microparticles to Promote Drug Entrapment into the Buccal Mucosa

2021

The currently available antifungal therapy for oral candidiasis (OC) has various limita- tions restricting its clinical use, such as short retention time, suboptimal drug concentration and low patients compliance. These issues could be overcome using micro or nanotechnology. In par- ticular, solid lipid microparticles (SLMs) resulted as a particularly promising penetration enhancer carrier for lipophilic drugs, such as the antifungal miconazole (MCZ). Based on these considera- tions, cetyl decanoate (here synthesized without the use of metal catalysis) was employed together with 1-hexadecanol to prepare MCZ-loaded SLMs. These resulted in a powder composed of 45–300 µm diameter solid spheric…

Drugbuccal filmmedia_common.quotation_subjectPharmaceutical SciencemiconazoleBuccal mucosaArticleDosage formbuccal gelEntrapmentPharmacy and materia medicaoral candidiasismedicineex vivo studiemedia_commonChromatographycetyl decanoateChemistryex vivo studiesBuccal administrationPermeationoral candidiasiRS1-441mucosal deliverySettore CHIM/09 - Farmaceutico Tecnologico Applicativopenetration enhancersolid lipid microparticlebuccal mucosasolid lipid microparticlesMiconazoleEx vivomedicine.drugPharmaceutics
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir

2008

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) studies were also taken into consideration in order to ascertain whether a biowaiver can be recommended. According to the Biopharmaceutics Classification System (BCS) and considering tablet strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries also 800 mg tablets are available which …

Drugbusiness.industrymedia_common.quotation_subjectAcyclovirAdministration OralBiological Availabilityvirus diseasesPharmaceutical ScienceExcipientPharmacologyBioequivalenceBiopharmaceutics Classification SystemAntiviral AgentsDosage formTherapeutic EquivalencyPharmacokineticsmedicineRegulatory scienceAciclovirbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct

Galantamine delivery on buccal mucosa: permeation enhancement and design of matrix tablets

2009

The most important feature in transbuccal drug delivery is the low drug passage through the buccal mucosa. In our previous work we demonstrated the aptitude of Galantamine to penetrate the buccal tissue. The collected data suggested that Galantamine passively crosses the membrane, but the calculated Js and Kp values showed that the drug amount that crosses the membrane wasn’t sufficient to assure blood therapeutic level. So, in this study, ex vivo permeation tests, using porcine buccal mucosa, were performed in presence of physical or chemical enhancers. No significant differences in penetration rate were observed using chemical enhancers as sodium dehydrocholate, EDTA disodium salt and tri…

Drugbusiness.industrymedia_common.quotation_subjectPharmaceutical ScienceBuccal administrationPharmacologyPermeationBuccal mucosaDosage formstomatognathic systemSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryGalantamineMedicineTransbuccal delivery Galantamine Permeation enhancement Alzheimer’s diseasebusinessEx vivomedicine.drugmedia_common
researchProduct

Transdermal therapy and diagnosis by iontophoresis

1997

Iontophoresis, the use of an electric current to drive charged molecules across the skin, has the potential to expand the feasible range of drugs for transdermal administration significantly. This method of delivery is being examined carefully with respect to higher-molecular-weight therapeutics (in particular, peptides and small proteins), which cannot be absorbed following oral administration and for which, at this time, an invasive injection remains the only option. In addition, the procedure of so-called 'reverse' iontophoresis would appear to represent a truly noninvasive approach for diagnostic monitoring of blood chemistry.

Drugddc:615Skin Diseases/diagnosis/therapyPeptides/administration & dosageIontophoresisbusiness.industrymedia_common.quotation_subjectBiotechnology/trendsBioengineeringIontophoresis/methodsIontophoresisPharmacologyAdministration CutaneousDiagnostic monitoringSkin DiseasesBlood chemistryOral administrationHumansMedicinePeptidesbusinessBiotechnologymedia_commonTransdermalTrends in Biotechnology
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride.

2021

Abstract Data are examined regarding possible waiver of in vivo bioequivalence testing (i.e. biowaiver) for approval of metformin hydrochloride (metformin) immediate-release solid oral dosage forms. Data include metformin's Biopharmaceutics Classification System (BCS) properties, including potential excipient interactions. Metformin is a prototypical transporter-mediated drug and is highly soluble, but only 50% of an orally administered dose is absorbed from the gut. Therefore, metformin is a BCS Class III substance. A BCS-based approval approach for major changes to marketed products and new generics is admissible if test and reference dosage forms have the identical active pharmaceutical …

Drugendocrine system diseasesmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralBiological Availabilitytransporters02 engineering and technologyPharmacologyBioequivalence030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceutics03 medical and health sciencesMetformin hydrochloride0302 clinical medicinePharmacokineticsmedicineBiopharmaceutics Classification System (BCS)media_commonActive ingredientDosage FormsbioequivalenceexcipientsChemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverMetforminMetforminSolubilityTherapeutic Equivalencyregulatory science0210 nano-technologypharmacokineticsmedicine.drugJournal of pharmaceutical sciences
researchProduct

Pectin as Drug-Release Vehicle

2020

Pectin as a natural biopolymer is extensively used for pharmaceutical and biomedical applications, essentially due to its gelling properties that could be influenced by pectin sources and extraction methods. This chapter focuses on an overview of pectin drug delivery systems classified by their administration routes. Oral drug delivery systems have been mainly developed, as pectin could be used in tablets as binder or matrix excipients and in microparticles/beads obtained by ionotropic gelation. The main objective is to target the colon, as pectin is resistant in acidic pH and sensitive to pectinolytic enzymes in the colon. To obtain suitable properties, pectin could be used in its native s…

Drugfood.ingredientPectinmedia_common.quotation_subject02 engineering and technologyengineering.material010402 general chemistryPolysaccharidecomplex mixtures01 natural sciencesDosage formfoodComputingMilieux_MISCELLANEOUSmedia_commonchemistry.chemical_classificationChromatographydigestive oral and skin physiologyfood and beveragesChemical modificationBuccal administration021001 nanoscience & nanotechnology0104 chemical sciences3. Good healthchemistryDrug deliveryengineeringBiopolymer0210 nano-technology[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC

2013

The Biopharmaceutics Classification System (BCS) has found widespread utility in drug discovery, product development and drug product regulatory sciences. The classification scheme captures the two most significant factors influencing oral drug absorption; solubility and intestinal permeability and it has proven to be a very useful and a widely accepted starting point for drug product development and drug product regulation. The mechanistic base of the BCS approach has, no doubt, contributed to its wide spread acceptance and utility. Nevertheless, underneath the simplicity of BCS are many detailed complexities, both in vitro and in vivo which must be evaluated and investigated for any given…

Drugmedia_common.quotation_subjectAdministration OralPharmaceutical ScienceComputational biologyPharmacologyModels BiologicalPermeabilityArticleIntestinal absorptionQuality by DesignDosage formBiopharmaceuticsIVIVCIn vivoTerminology as TopicAnimalsHumansTechnology PharmaceuticalComputer SimulationPharmacokineticsIntestinal Mucosamedia_commonChemistryBiopharmaceuticsReproducibility of ResultsHydrogen-Ion ConcentrationBiopharmaceutics Classification SystemIntestinal AbsorptionPharmaceutical PreparationsSolubilityEuropean Journal of Pharmaceutical Sciences
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine.

2020

Abstract Literature relevant to assessing whether BCS-based biowaivers can be applied to immediate release (IR) solid oral dosage forms containing carbamazepine as the single active pharmaceutical ingredient are reviewed. Carbamazepine, which is used for the prophylactic therapy of epilepsy, is a non-ionizable drug that cannot be considered “highly soluble” across the range of pH values usually encountered in the upper gastrointestinal tract. Furthermore, evidence in the open literature suggests that carbamazepine is a BCS Class 2 drug. Nevertheless, the oral absolute bioavailability of carbamazepine lies between 70 and 78% and both in vivo and in vitro data support the classification of ca…

Drugmedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formBiopharmaceuticsExcipients03 medical and health sciences0302 clinical medicineIVIVCTherapeutic indexmedicineImmediate releasemedia_commonActive ingredientDosage Formsbusiness.industryCarbamazepine021001 nanoscience & nanotechnologyCarbamazepineSolubilityTherapeutic Equivalency0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid.

2012

A biowaiver monograph for acetylsalicylic acid (ASA) is presented. Literature and experimental data indicate that ASA is a highly soluble and highly permeable drug, leading to assignment of this active pharmaceutical ingredient (API) to Class I of the Biopharmaceutics Classification System (BCS). Limited bioequivalence (BE) studies reported in the literature indicate that products that have been tested are bioequivalent. Most of the excipients used in products with a marketing authorization in Europe are not considered to have an impact on gastrointestinal motility or permeability. Furthermore, ASA has a wide therapeutic index. Thus, the risks to the patient that might occur if a nonbioequi…

Drugmedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyBioequivalenceMarketing authorizationDosage formDrug StabilityFibrinolytic AgentsAnimalsHumansCyclooxygenase Inhibitorsmedia_commonActive ingredientAspirinChemistryAnti-Inflammatory Agents Non-SteroidalBiopharmaceutics Classification SystemSolubilityTherapeutic EquivalencyPlatelet aggregation inhibitorCaco-2 CellsFibrinolytic agentPlatelet Aggregation InhibitorsTabletsJournal of pharmaceutical sciences
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.

2019

Literature data and results of experimental studies relevant to the decision to allow waiver of bioequivalence studies in humans for the approval of immediate release solid oral dosage forms containing cephalexin monohydrate are presented. Solubility studies were performed in accordance with the current biowaiver guidelines of the Food and Drug Administration, World Health Organization and European Medicines Agency, taking the degradation at some pH values into consideration. Together with solubility and permeability data for cephalexin monohydrate from the literature, it was demonstrated to be a Biopharmaceutics Classification System Class 1 drug. The pharmacokinetic behavior, results of b…

Drugmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicinemedicineBiopharmaceutics Classification System (BCS)HumansRegulatory scienceLADME characteristicsmedia_commonActive ingredientcephalexin monohydrateDosage FormsbioequivalenceCephalexinexcipientsbusiness.industryBiopharmaceutics021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemSolubilityTherapeutic Equivalencyregulatory science0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct